Search

Agios Pharmaceuticals Inc

Aperta

SettoreSettore sanitario

33.83 3.96

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

32.4

Massimo

34.15

Metriche Chiave

By Trading Economics

Entrata

-1.6M

-101M

Vendite

24M

45M

EPS

-1.69

Margine di Profitto

-225.06

Dipendenti

539

EBITDA

-11M

-109M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+26.62% upside

Dividendi

By Acuity

Utili prossimi

29 ott 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-191M

2B

Apertura precedente

29.87

Chiusura precedente

33.83

Notizie sul Sentiment di mercato

By Acuity

50%

50%

150 / 340 Classifica in Healthcare

Agios Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 ago 2026, 19:36 UTC

Agios Pharmaceuticals Inc shares are lower today, continuing a decline since Friday's close amid broader market volatility linked to geopolitical events.

21 ago 2026, 19:36 UTC

Agios Pharmaceuticals Inc shares are lower during Friday's session amid rising U.S. Treasury yields and ongoing geopolitical tensions. No specific news was identified.

20 ago 2026, 20:01 UTC

News

Agios Pharmaceuticals Inc. shares are lower today, driven by a significant downturn in the Biotechnology sector and heightened trading volume.

19 ago 2026, 20:06 UTC

Agios Pharmaceuticals shares are higher today, though they pulled back from a session high. Broader market sentiment may be influenced by rising cryptocurrency values.

18 ago 2026, 22:51 UTC

Agios Pharmaceuticals shares are lower in after-market hours, amid broader negative sentiment linked to rising sovereign bond yields and persistent inflation risks.

17 ago 2026, 19:41 UTC

News

Agios Pharmaceuticals shares are rising as Cantor Fitzgerald maintains an Overweight rating ahead of the November 1 PDUFA date for mitapivat.

14 ago 2026, 19:46 UTC

Agios Pharmaceuticals Inc shares are higher today, though no specific news explains the movement. Earlier, shares peaked before dipping later in the session.

12 ago 2026, 20:01 UTC

Agios Pharmaceuticals Inc shares are higher today amid unusually high trading volume. The stock has gained significantly since Tuesday's close.

11 ago 2026, 19:26 UTC

Agios Pharmaceuticals Inc shares are higher today, with no specific news driving the move. Market focus remains on upcoming U.S. inflation reports.

10 ago 2026, 21:01 UTC

Agios Pharmaceuticals Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains below its 20-day moving average.

6 ago 2026, 19:32 UTC

Agios Pharmaceuticals shares are higher today, continuing an upward trend since Wednesday. The stock peaked earlier in the session before a slight pullback.

5 ago 2026, 19:56 UTC

News

Agios Pharmaceuticals is under investigation regarding its decision on tebapivat, contributing to lower trading activity today amid ongoing investor concerns.

4 ago 2026, 20:02 UTC

Agios Pharmaceuticals Inc shares are higher today amid broader market gains, supported by falling crude oil prices and comments on potential peace talks with Iran.

3 ago 2026, 20:06 UTC

Agios Pharmaceuticals Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

31 lug 2026, 22:51 UTC

Agios Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market declines amid mixed tech earnings and rising U.S. Treasury yields.

30 lug 2026, 20:08 UTC

Agios Pharmaceuticals shares are lower today amid mixed economic signals and unusually high trading volume. The stock has declined since Wednesday's close.

29 lug 2026, 20:51 UTC

Agios Pharmaceuticals Inc shares gained in after-market trading, rebounding from a session low despite broader market pressures from rising crude oil prices and geopolitical tensions.

28 lug 2026, 20:02 UTC

News

Agios Pharmaceuticals shares are lower amid an investigation into potential claims following the halted development of tebapivat for sickle cell disease.

27 lug 2026, 20:01 UTC

Agios Pharmaceuticals Inc shares are higher during Monday's session, reaching a notable peak earlier in the day. No specific news was identified for the move.

24 lug 2026, 23:21 UTC

Agios Pharmaceuticals shares are higher in after-market trading, supported by a decline in initial jobless claims, indicating a robust labor market.

22 lug 2026, 22:41 UTC

Agios Pharmaceuticals shares are lower in after-market trading, continuing a three-session decline amid broader market concerns over rising crude oil prices and inflation.

21 lug 2026, 19:01 UTC

News
Event
Social Media

Agios Pharmaceuticals shares declined after discontinuing tebapivat development for sickle cell disease, despite some trial improvements. The stock remains lower since Monday's close.

Confronto tra pari

Modifica del prezzo

Agios Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

26.62% in crescita

Previsioni per 12 mesi

Media 41.33 USD  26.62%

Alto 55 USD

Basso 31 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Agios Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

9 ratings

6

Acquista

3

Mantieni

0

Vendi

Sentiment

By Acuity

150 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat